Form 4: Alkermes Executive Trades Shares Under 10b5-1 Plan

Alkermes plc reports significant stock transactions by EVP R&D, Craig C. Hopkinson, executed under a pre-arranged trading plan.

Summary

• Craig C. Hopkinson, EVP R&D and Chief Medical Officer at Alkermes plc, engaged in stock transactions on July 1, 2026.
• These transactions included the exercise of 5,000 employee stock options at a price of $19.34 per share.
• Concurrently, 8,300 ordinary shares were sold at a weighted average price of $51.46, and an additional 700 ordinary shares were sold at a weighted average price of $52.13.
• All transactions were conducted under a Rule 10b5-1 trading plan established on March 14, 2025, which is designed to comply with affirmative defense conditions.
• Following these transactions, Mr. Hopkinson beneficially owns 73,389 ordinary shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. While it involves significant share sales by an executive, the execution under a pre-established Rule 10b5-1 plan mitigates concerns about insider knowledge and suggests a planned financial strategy rather than a reaction to negative company developments.

Positives

• Transactions were executed under a Rule 10b5-1 plan, indicating pre-planned and potentially strategic financial management by the executive.
• The executive's stock options were fully vested, suggesting continued commitment and reward realization.
• The sale prices ($51.46 and $52.13) are significantly higher than the option exercise price ($19.34), indicating a profitable outcome for the exercised options.

Negatives

• A significant number of shares (9,000 total) were sold by a key executive, which could be interpreted negatively by the market.
• The filing does not provide specific reasons for the sale beyond the execution of the 10b5-1 plan.

Risks

• The sale of a substantial number of shares by a high-ranking executive could signal a lack of confidence in future stock performance, although this is mitigated by the Rule 10b5-1 plan.
• Market perception of insider selling, even when pre-planned, can negatively impact stock price.

Future Outlook

The filing itself does not contain forward-looking statements or guidance regarding the company's future performance. It solely reports on past transactions by an executive.

Management Comments

• The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025.
• Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request.

Industry Context

StockSavvy.ai notes that Form 4 filings detailing executive stock transactions are common in the biopharmaceutical industry. The use of Rule 10b5-1 plans by executives is a standard practice to diversify holdings or manage personal finances while adhering to insider trading regulations.

Stakeholder Impact

• Shareholders: May interpret the sale of shares by an executive as a negative signal, though the Rule 10b5-1 plan provides a mitigating context.
• Employees: The executive's stock option exercise and sale could be seen as a reward realization, but also might raise questions about future stock growth.
• Management: Demonstrates adherence to regulatory requirements for insider trading through the use of a 10b5-1 plan.

Next Steps

• The reporting person will continue to hold 73,389 ordinary shares.
• Further transactions by this executive would be reported on subsequent Form 4 filings.

Key Dates

Keywords

Alkermes plc, ALKS, Form 4, Insider Trading, Stock Options, Share Sale, Rule 10b5-1, Executive Compensation, Beneficial Ownership, SEC Filing